BCL6 and chronic myelogenous leukemia, BCR-ABL1 positive: Increased expression of BCL6 in chronic myelogenous leukemia (CML) and ALL has been shown to protect leukemic cells from chemotherapy-induced DNA damage through the repression of p53-induced apoptosis [19–20].